Recent studies have identified that METTL14/m6A-mediated epitranscriptomic alterations disrupt ADRB signaling in adipose tissue, contributing to the development of obesity, NAFLD, and other metabolic disorders (Kang et al., 2023). Here, METTL14 is linked to metabolic dysfunction-associated steatotic liver disease.